These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 232936)

  • 1. Experimental animal models for anaerobic infections.
    Onderdonk AB; Kasper DL; Mansheim BJ; Louie TJ; Gorbach SL; Bartlett JG
    Rev Infect Dis; 1979; 1(2):291-301. PubMed ID: 232936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of metronidazole in anaerobic bacteria.
    Tally FP; Goldin BR; Sullivan N; Johnston J; Gorbach SL
    Antimicrob Agents Chemother; 1978 Mar; 13(3):460-5. PubMed ID: 233729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):946-9. PubMed ID: 1486894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis.
    Bartlett JG; Louie TJ; Gorbach SL; Onderdonk AB
    Rev Infect Dis; 1981; 3(3):535-42. PubMed ID: 7025151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
    Pefanis A; Thauvin-Eliopoulos C; Holden J; Eliopoulos GM; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):252-5. PubMed ID: 8192453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
    Brook I; Ledney GD
    J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal antimicrobial synergism between Escherichia coli and Bacteroides fragilis in the presence of metronidazole.
    Soriano F; Ponte MC; Gaspar MC
    J Clin Pathol; 1982 Oct; 35(10):1150-2. PubMed ID: 6752209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to chloramphenicol and metronidazole in anaerobic bacteria.
    Britz ML
    J Antimicrob Chemother; 1981 Dec; 8 Suppl D():49-57. PubMed ID: 6279556
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
    Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
    J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antimicrobial therapy on mixed infections with Bacteroides species. Is eradication of the anaerobes important?
    Brook I
    J Infect; 1991 Jan; 22(1):27-35. PubMed ID: 2002230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined activity of metronidazole and gentamicin on Bacteroides fragilis in vivo and in vitro.
    Dijkmans BA; Vaishnav J; Mattie H
    J Antimicrob Chemother; 1985 Jan; 15(1):77-82. PubMed ID: 3882656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains.
    Onderdonk AB; Kasper DL; Cisneros RL; Bartlett JG
    J Infect Dis; 1977 Jul; 136(1):82-9. PubMed ID: 886206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
    Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice.
    Dijkmans BA; Vaishnav J; Mattie H
    Chemotherapy; 1985; 31(4):297-303. PubMed ID: 4028873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
    Beale AS; Gisby J
    J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.